Local Coverage DeterminationAllergy/Immunology

LCD L40048: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) — NGS

LCD-L40048

Document details

Document type
Local Coverage Determination
Issuing body
MAC Contractor
Document ID
LCD-L40048
Published
June 5, 2026
Effective date
October 26, 2025
MAC region
National Government Services

Summary

The introduction of the LCD for Allergen Immunotherapy with SCIT may impact the billing process for practices providing these services. Providers will need to ensure compliance with the new guidelines

New AIT LCD effective 10/26/2025 may affect billing.

Affected codes

ICD-10-CM

Affected specialty

Allergy/Immunology alerts →

Source document

https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=40048&ver=5

CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.

Related alerts

4

Proposed LCD DL40050: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) — Noridian

Policy LCD-DL40050 · Allergy/Immunology

High

The proposed Local Coverage Determination (LCD) on Allergen Immunotherapy may impact billing practices for providers offering subcutaneous immunotherapy. It could lead to higher reimbursement rates fo

View alert

Proposed LCD DL40052: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) — Noridian

Policy LCD-DL40052 · Allergy/Immunology

High

The proposed LCD for Allergen Immunotherapy may significantly influence billing practices related to Subcutaneous Immunotherapy. Providers will need to ensure proper documentation and coding align wit

View alert

Proposed LCD DL40048: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) — NGS

Policy LCD-DL40048 · Allergy/Immunology

High

The proposed LCD for Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) could have significant billing implications, particularly for allergists and practices specializing in immunoth

View alert

Proposed LCD DL39314: Off-Label Use of Intravenous Immune Globulin (IVIG) — NGS

Policy LCD-DL39314 · Allergy/Immunology

High

The proposed LCD addresses the billing implications for off-label uses of IVIG, which may affect reimbursement rates and eligibility for coverage under Medicare. Providers need to stay informed about

View alert